$2.32
3.35% today
Nasdaq, Aug 12, 07:11 pm CET
ISIN
US00773U1088
Symbol
ADVM

Adverum Biotechnologies Inc Stock price

$2.24
-0.30 11.81% 1M
-1.79 44.42% 6M
-2.43 52.03% YTD
-4.25 65.49% 1Y
-12.86 85.17% 3Y
-153.66 98.56% 5Y
-137.06 98.39% 10Y
-277.66 99.20% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.05 2.18%
ISIN
US00773U1088
Symbol
ADVM
Industry

Key metrics

Basic
Market capitalization
$46.8m
Enterprise Value
$-36.3m
Net debt
positive
Cash
$83.1m
Shares outstanding
20.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 241.5
EV/Sales
- | negative
EV/FCF
0.3
P/B
1.8
Financial Health
Equity Ratio
39.3%
Return on Equity
-185.2%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $193.8k
EBITDA
- | $-198.9m
EBIT
- | $-188.4m
Net Income
- | $-129.9m
Free Cash Flow
$-112.5m
Growth (TTM | estimate)
Revenue
- | -80.6%
EBITDA
- | -46.8%
EBIT
- | -35.4%
Net Income
- | 0.8%
Free Cash Flow
-21.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -102,631.6%
EBIT
-
Net
- | -67,043.9%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-5.4
Short interest
5.6%
Employees
155
Rev per Employee
$10.0k
Show more

Is Adverum Biotechnologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Adverum Biotechnologies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

Buy
83%
Hold
17%

Financial data from Adverum Biotechnologies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1 1
72% 72%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
22% 22%
6,076%
- Research and Development Expense 77 77
1% 1%
7,704%
-133 -133
13% 13%
-13,315%
- Depreciation and Amortization 3.65 3.65
35% 35%
365%
EBIT (Operating Income) EBIT -137 -137
11% 11%
-13,680%
Net Profit -129 -129
10% 10%
-12,857%

In millions USD.

Don't miss a Thing! We will send you all news about Adverum Biotechnologies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adverum Biotechnologies Inc Stock News

Neutral
GlobeNewsWire
about 7 hours ago
-  ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD -  ARTEMIS enrollment completion expected in 1Q 2026, with topline data anticipated 1H 2027 -  LUNA 2-year long-term follow-up data planned in 4Q 2025 -  Announced $10 million private placement with Frazier Life Sciences REDWOOD ...
Neutral
GlobeNewsWire
6 days ago
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual ...
Neutral
GlobeNewsWire
2 months ago
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 201...
More Adverum Biotechnologies Inc News

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Head office United States
CEO Laurent Fischer
Employees 155
Founded 2006
Website adverum.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today